Meeting
2016 ASCO Annual Meeting
Tamoxifen versus aromatase inhibitors for the adjuvant treatment of breast cancer in older women: A feasibility study to examine differences in cognitive outcomes.
Authors
Emily Anne Underwood
Sunnybrook Research Institute, Toronto, ON, Canada
Emily Anne Underwood , Katarzyna Joanna Jerzak , Kathleen I. Pritchard , Mary Catherine Tierney
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—HER2/ER
Track
Breast Cancer
Sub Track
ER+
Clinical Trial Registration Number
NCT02480218
Citation
J Clin Oncol 34, 2016 (suppl; abstr TPS626)
DOI
10.1200/JCO.2016.34.15_suppl.TPS626
Abstract #
TPS626
Poster Bd #
107b
Abstract Disclosures
Similar Posters
Poster
2011 ASCO Annual Meeting
Effects of body mass index (BMI) on plasma levels of estrone sulfate (ES) in postmenopausal women with breast cancer (BC) during letrozole (L) treatment.
First Author: G. Lunardi
Poster
2018 Palliative and Supportive Care in Oncology Symposium
Switching endocrine therapy in breast cancer as a strategy for musculoskeletal symptoms, tolerance, and adherence.
First Author: Albina Kibirova
Poster
2012 Breast Cancer Symposium
Vascular toxicities of endocrine therapy in early-stage breast cancer: Encouraging observations in a nontrial setting.
First Author: Susan Dent
Poster
2023 ASCO Annual Meeting
Evolving adjuvant estrogen therapy prescribing among breast oncology workforce.
First Author: Kayla Polcari